Brief: Adverum Biotechnologies Inc Finalizing Two-Dose Study Design For Phase 2 Trial Of ADVM-022 In Wet Amdwith Intention To Dose First Patient In Q32022

Adverum Biotechnologies

21/12/2021 13:08

Dec 21 (Reuters) - Adverum Biotechnologies Inc  ADVM.O :
    * ADVERUM BIOTECHNOLOGIES INC - FINALIZING TWO-DOSE STUDY
DESIGN
FOR PHASE 2 TRIAL OF ADVM-022 IN WET AMDWITH INTENTION TO DOSE
FIRST PATIENT IN Q32022
    * ADVERUM BIOTECHNOLOGIES INC - ANTICIPATES NEAR-TERM HIRES
TO
FURTHER STRENGTHEN EXECUTIVE TEAM
    * ADVERUM BIOTECHNOLOGIES INC - EXPECTS CASH POSITION TO
FUND
DEVELOPMENT PLANS AND OPERATIONS INTO 2024
    * ADVERUM BIOTECHNOLOGIES - INTENDS TO FILE IND AMENDMENT IN
H1 OF
2022, ENGAGE WITH FDA WITH AIM OF SECURING AGREEMENT ON PHASE 2
TRIAL DESIGN
    * ADVERUM BIOTECHNOLOGIES INC - PLAN TO DOSE FIRST PATIENT
IN
PHASE 2 TRIAL OF ADVM-022 IN WET AMD IN THIRD QUARTER 2022

Source text for Eikon:  ID:nGNX7hxWGS 
Further company coverage:  ADVM.O